Holders — by stockHoldings — by fund
GREAT POINT PARTNERS LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001281446
$529.1M
disclosed book value
41
positions
10.1%
largest position share
Positions, as of 2026-06-30
top 42 of 41 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | ABVXABIVAX SACALL | 400,000 | $53.3M | 10.1% |
| 2 | VORVOR BIOPHARMA INC | 1.7M | $31.3M | 5.9% |
| 3 | ABVXABIVAX SA | 204,314 | $27.2M | 5.1% |
| 4 | IBRXIMMUNITYBIO INCPUT | 3.0M | $26.3M | 5% |
| 5 | VERAVERA THERAPEUTICS INC | 600,836 | $25.8M | 4.9% |
| 6 | ZURA BIO LTD | 4.2M | $24.9M | 4.7% |
| 7 | ALMSALUMIS INC | 856,061 | $24.1M | 4.6% |
| 8 | SOL-GEL TECHNOLOGIES LTD | 274,363 | $20.3M | 3.8% |
| 9 | RAREULTRAGENYX PHARMACEUTICAL INPUT | 600,000 | $20.0M | 3.8% |
| 10 | DFTXDEFINIUM THERAPEUTICS INC | 425,000 | $20.0M | 3.8% |
| 11 | ANNXANNEXON INC | 3.5M | $20.0M | 3.8% |
| 12 | ORKAORUKA THERAPEUTICS INC | 183,330 | $17.4M | 3.3% |
| 13 | MLTXMOONLAKE IMMUNOTHERAPEUTICS | 855,813 | $16.7M | 3.1% |
| 14 | SGMTSAGIMET BIOSCIENCES INC | 2.0M | $15.7M | 3% |
| 15 | CTNMCONTINEUM THERAPEUTICS INC | 921,481 | $15.1M | 2.9% |
| 16 | IMMXIMMIX BIOPHARMA INC | 1.3M | $13.2M | 2.5% |
| 17 | CLYMCLIMB BIO INC | 1.0M | $13.0M | 2.5% |
| 18 | AMLXAMYLYX PHARMACEUTICALS INC | 700,000 | $12.6M | 2.4% |
| 19 | NKTRNEKTAR THERAPEUTICS | 175,000 | $12.2M | 2.3% |
| 20 | NGNENEUROGENE INC | 352,180 | $11.1M | 2.1% |
| 21 | LBRXLB PHARMACEUTICALS INC | 317,221 | $10.3M | 1.9% |
| 22 | IRDOPUS GENETICS INC | 2.0M | $8.1M | 1.5% |
| 23 | EPRXEUPRAXIA PHARMACEUTICALS INC | 1.2M | $7.9M | 1.5% |
| 24 | DRUGBRIGHT MINDS BIOSCIENCES INC | 109,603 | $7.7M | 1.5% |
| 25 | INFLARX NV | 3.0M | $6.8M | 1.3% |
| 26 | RLMDRELMADA THERAPEUTICS INC | 842,106 | $5.8M | 1.1% |
| 27 | JATT II ACQUISITION CORP | 500,000 | $5.7M | 1.1% |
| 28 | CGEMCULLINAN THERAPEUTICS INC | 300,000 | $5.5M | 1% |
| 29 | ALTALTIMMUNE INC | 1.7M | $5.3M | 1% |
| 30 | AMANAT ACQUISITION CORP | 500,000 | $5.1M | 1% |
| 31 | RZLTREZOLUTE INC | 951,809 | $4.9M | 0.9% |
| 32 | SLNSILENCE THERAPEUTICS PLC | 450,000 | $4.9M | 0.9% |
| 33 | PALIPALISADE BIO INC | 2.3M | $4.8M | 0.9% |
| 34 | EVMNEVOMMUNE INC | 325,000 | $4.3M | 0.8% |
| 35 | SCYXSCYNEXIS INC | 944,292 | $3.8M | 0.7% |
| 36 | GALTGALECTIN THERAPEUTICS INCCALL | 800,000 | $3.7M | 0.7% |
| 37 | ELVNENLIVEN THERAPEUTICS INC | 70,000 | $3.6M | 0.7% |
| 38 | HUMAHUMACYTE INC | 3.8M | $2.9M | 0.6% |
| 39 | RNTXREIN THERAPEUTICS INC | 2.6M | $2.7M | 0.5% |
| 40 | DBVTDBV TECHNOLOGIES S A | 156,906 | $2.6M | 0.5% |
| 41 | AVXLANAVEX LIFE SCIENCES CORPCALL | 521,300 | $1.4M | 0.3% |
| 42 | PMNPROMIS NEUROSCIENCES INC | 86,150 | $1.1M | 0.2% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.